Literature DB >> 12059121

Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene.

Jill Waalen1, Vincent Felitti, Terri Gelbart, Ngoc J Ho, Ernest Beutler.   

Abstract

OBJECTIVE: To determine the prevalence of hemochromatosis-related symptoms in homozygotes for the HFE mutation C282Y compared with controls without HFE mutations identified through a large screening program of subjects attending a health appraisal center. SUBJECTS AND METHODS: Presence of symptoms commonly associated with clinical hemochromatosis was ascertained by self-report on a written questionnaire among C282Y homozygotes and HFE wild-type subjects of white or Hispanic ethnicity identified from screening 41,599 adult subjects between March 1999 and August 2001. A subset of C282Y homozygotes and wild-type subjects identified from 12,756 subjects attending the center in the final year of the study completed a standardized double-blind interview with a physician regarding the presence, duration, and severity of a larger set of symptoms. Prevalence of symptoms among C282Y homozygotes and wild-type controls ascertained by written questionnaire and interview were compared by chi2 analysis or Fisher exact test. Symptoms among subjects with other combinations of the C282Y and H63D HFE mutations were also assessed by questionnaire.
RESULTS: The 124 C282Y homozygotes who filled out the written questionnaire and the 17 C282Y homozygotes who completed the physician double-blind interview reported no significantly higher rates of arthritis or joint pain, abdominal pain, arrhythmias, darkening of skin, or other symptoms traditionally associated with hemochromatosis compared with the 22,429 wild-type controls who filled out the written questionnaire and 29 wild-type controls who completed the double-blind interview. The only symptom reported more frequently by C282Y homozygotes was loss of body hair, reported by 5 C282Y/C282Y female subjects compared with 1 wild-type male subject (P=.02) in the physician interview. Symptoms among subjects with other HFE genotypes were similar to symptoms of wild-type subjects.
CONCLUSIONS: Results of this study indicate that many of the symptoms associated with hemochromatosis are common among HFE wild types and that clinical penetrance of the C282Y/C282Y genotype in regard to these symptoms is low.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12059121     DOI: 10.4065/77.6.522

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  21 in total

1.  Penetrance of haemochromatosis.

Authors:  E Beutler
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

2.  Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection.

Authors:  Mark Thursz
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

Review 3.  Cutaneous manifestations of common liver diseases.

Authors:  Sunil Dogra; Rashmi Jindal
Journal:  J Clin Exp Hepatol       Date:  2012-01-02

4.  Hematologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume.

Authors:  Ernest Beutler; Carol West
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

5.  Normal iron metabolism and the pathophysiology of iron overload disorders.

Authors:  Chiang W Siah; John Ombiga; Leon A Adams; Debbie Trinder; John K Olynyk
Journal:  Clin Biochem Rev       Date:  2006-02

6.  The H63D variant in the HFE gene predisposes to arthralgia, chondrocalcinosis and osteoarthritis.

Authors:  B Z Alizadeh; O T Njajou; J M W Hazes; A Hofman; P E Slagboom; H A P Pols; C M van Duijn
Journal:  Ann Rheum Dis       Date:  2007-02-06       Impact factor: 19.103

Review 7.  Screening for hemochromatosis: patients with liver disease, families, and populations.

Authors:  Sumedha P Galhenage; Charlie H Viiala; John K Olynyk
Journal:  Curr Gastroenterol Rep       Date:  2004-02

8.  A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.

Authors:  Nancy L Bartlett; Anas Younes; Matthew H Carabasi; Andres Forero; Joseph D Rosenblatt; John P Leonard; Steven H Bernstein; R Gregory Bociek; Jennie M Lorenz; Bruce W Hart; Jeremy Barton
Journal:  Blood       Date:  2007-12-13       Impact factor: 22.113

9.  Screening for hemochromatosis by measuring ferritin levels: a more effective approach.

Authors:  Jill Waalen; Vincent J Felitti; Terri Gelbart; Ernest Beutler
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

10.  Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS study initial screening.

Authors:  James C Barton; Ronald T Acton; Catherine Leiendecker-Foster; Laura Lovato; Paul C Adams; John H Eckfeldt; Christine E McLaren; Jacob A Reiss; Gordon D McLaren; David M Reboussin; Victor R Gordeuk; Mark R Speechley; Richard D Press; Fitzroy W Dawkins
Journal:  Am J Hematol       Date:  2008-02       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.